

Performance Against Delivery Benchmark

| Count | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial  | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed | Maximum Number Of Patients Agreed | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure   |
|-------|--|---|--|-----------------------------------|-----------------------------------|-----------------------------------|---|--|--|---|--|----------------------|
| 1     | 17/EM/0355                                 | 229043  | SPIRIT 2 #   | Number Agreed                     | 4                                 | 4                                 | Date Agreed                             | 28/02/2019                                       | 0  | 28/02/2019                                | 0  | Withdrawn By Host    |
| 2     | 17/EE/0437                                 | 233853  | AQUILA (54767414SMM3001)   | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 13/12/2019                                       | 4  | 07/03/2019                                | 4  | Recruitment Finished |
| 3     | 18/EM/0228                                 | 248988  | Anti-viral effect of PC786 on RSV infection in HSCT recipients         | Number Agreed                     | 3                                 | 3                                 | Date Agreed                             | 11/03/2019                                       | 2  | 11/03/2019                                | 2  | Recruitment Finished |
| 4     | 18/LO/0378                                 | 234232  | PIONEER III  | Number Agreed                     | 12                                | 12                                | Date Agreed                             | 30/06/2019                                       | 6  | 15/03/2019                                | 6  | Recruitment Finished |
| 5     | 18/SW/0050                                 | 235126  | A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC           | Number Agreed                     | 1                                 | 1                                 | Date Agreed                             | 30/04/2019                                       | 1  | 02/04/2019                                | 1  | Recruitment Finished |
| 6     | 17/NI/0096                                 | 225743  | HOPE-1   | Number Agreed                     | 3                                 | 3                                 | Date Agreed                             | 30/04/2019                                       | 3  | 29/04/2019                                | 3  | Recruitment Finished |
| 7     | 14/LO/0566                                 | 145475  | CANC - 3490 OLYMPIA  | Number Agreed                     | 3                                 | 3                                 | Date Agreed                             | 30/04/2019                                       | 30   | 30/04/2019                                | 30   | Recruitment Finished |
| 8     | 17/EE/0474                                 | 229785  | AdAPT: Adenovirus after Allogeneic Paediatric Transplantation          | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 31/05/2019                                       | 1  | 13/05/2019                                | 1  | Recruitment Finished |
| 9     | 17/SW/0221                                 | 232448  | (CAIN457K2340) Secukinumab compared with GP2017 in Active AS           | Number Agreed                     | 3                                 | 3                                 | Date Agreed                             | 30/06/2019                                       | 2  | 31/05/2019                                | 2  | Recruitment Finished |
| 10    | 18/LO/1238                                 | 245332  | Open Label Extension study of WVE-210201 in patients with DMD          | Number Agreed                     | 1                                 | 1                                 | Date Agreed                             | 30/06/2019                                       | 1  | 05/06/2019                                | 1  | Recruitment Finished |
| 11    | 15/YH/0478                                 | 186697  | HEPA - 5032 The REGENERATE Study                                       | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 30/07/2019                                       | 3  | 17/06/2019                                | 3  | Recruitment Finished |
| 12    | 18/LO/1311                                 | 248599  | GR40398 EFFICACY AND SAFETY OF RO6867461 IN DMO PATIENTS (RHINE) v1    | Number Agreed                     | 5                                 | 5                                 | Date Agreed                             | 30/11/2019                                       | 2  | 22/08/2019                                | 2  | Recruitment Finished |
| 13    | 18/WS/0137                                 | 247036  | VISION Study of 177Lu-PSMA-617 in the treatment of PSMA-Positive mCRPC | Number Agreed                     | 6                                 | 6                                 | Date Agreed                             | 22/08/2019                                       | 3  | 29/08/2019                                | 3  | Recruitment Finished |
| 14    | 19/EM/0003                                 | 251874  | Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy          | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 30/06/2020                                       | 4  | 03/09/2019                                | 4  | Recruitment Finished |
| 15    | 18/SC/0342                                 | 247085  | Phase III Trial of AMT-061 in adults with haemophilia B                | Number Agreed                     | 1                                 | 1                                 | Date Agreed                             | 30/09/2019                                       | 0  | 03/09/2019                                | 0  | Recruitment Finished |
| 16    | 18/WS/0172                                 | 251636  | 1011712  | Number Agreed                     | 5                                 | 5                                 | Date Agreed                             | 30/08/2019                                       | 0  | 04/09/2019                                | 0  | Withdrawn By Sponsor |
| 17    | 16/LO/0543                                 | 198734  | GMP Drink for PKU Study  | Number Agreed                     | 1                                 | 1                                 | Date Agreed                             | 31/12/2019                                       | 3  | 30/09/2019                                | 3  | Recruitment Finished |
| 18    | 18/WM/0190                                 | 240027  | Combi-Aplus: Dabrafenib + Trametinib in BRAF+ve Melanoma               | Number Agreed                     | 8                                 | 8                                 | Date Agreed                             | 29/08/2019                                       | 9  | 26/09/2019                                | 9  | Recruitment Finished |
| 19    | 17/NW/0022                                 | 219189  | Post-Authorization Study of HyQvia in Pediatric PIDD subjects          | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 31/12/2019                                       | 5  | 22/10/2019                                | 5  | Recruitment Finished |
| 20    | 17/YH/0392                                 | 230501  | BI 1467335 in patients with diabetic retinopathy.                      | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 31/10/2019                                       | 2  | 31/10/2019                                | 2  | Recruitment Finished |
| 21    | 19/EM/0047                                 | 257111  | GR40306 (TENAYA): A study of faricimab in nAMD                         | Number Agreed                     | 4                                 | 4                                 | Date Agreed                             | 31/12/2019                                       | 4  | 31/10/2019                                | 4  | Recruitment Finished |
| 22    | 19/YH/0067                                 | 254066  | CANOPY-1   | Number Agreed                     | 3                                 | 3                                 | Date Agreed                             | 21/10/2022                                       | 0  | 05/12/2019                                | 0  | Recruitment Finished |
| 23    | 19/NW/0482                                 | 269475  | Kepler   | Number Agreed                     | 2                                 | 2                                 | Date Agreed                             | 30/03/2020                                       | 2  | 19/12/2019                                | 2  | Recruitment Finished |